MicroSPECT imaging of triple negative breast cancer cell tumor xenografted in athymic mice with radioiodinated anti-ICAM-1 monoclonal antibody. (September 2018)

• Record Type: Journal Article
• Authors: You, Linyi; Wang, Xiangyu; Guo, Zhide; Zhang, Deliang; Zhang, Pu; Li, Jindian; Su, Xinhui; Pan, Weimin; Zhang, Xianzhong
• Is Part Of: Applied radiation and isotopes. Volume 139(2018:Sep.)
• Page Start: 20
• Page End: 25
• Publication Date: 2018-09
• Subjects: Radioiodination -- SPECT -- ICAM-1 -- Triple negative breast cancer; Radiology -- Periodicals; Radiation -- Industrial applications -- Periodicals; Nuclear chemistry -- Periodicals; Internet resource; Periodical; 660.298
• DOI: 10.1016/j.apradiso.2018.04.005
• Languages: English
• ISSNs: 0969-8043

Abstract

Abstract: Intercellular adhesion molecule-1(ICAM-1) is a potential molecular target and biomarker for triple negative breast cancer (TNBC) therapy and diagnosis. In this study, aICAM-1 was radioiodinated with 125 I/ 131 I in high radiochemical yield and the probes for TNBC tumor targeting and radioimmunotherapy were evaluated in tumor-bearing mice. High and specific accumulation of 125 I-aICAM1 in TNBC MDA-MB-231 tumor was observed in SPECT imaging and the tumor grew was inhibited obviously by 131 I-aICAM1. Thus, the radioiodinated aICAM1 could serve as potential agents for TNBC theranostics. Highlights: Radioiodination of aICAM1 was developed as a potential theranostic agent for TNBC tumor diagnosis and radioimmunotherapy. In vitro evaluation of radioiodinated aICAM1 showed that it has high affinity and could specifically target to TNBC cells. In vivo SPECT imaging of tumor-bearing mice with 125 I-aICAM1 demonstrated that it has high TNBC tumor uptake and T/NT ratio.